Loading...
NPI 1497034532 · Indianapolis, IN · Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Pharmaneek Inc is a pharmacy provider located in Indianapolis, Indiana. This profile covers 2 Medicare and 8 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Pharmaneek Inc |
| Address | 7345 Woodland Dr. |
| City | Indianapolis |
| State | IN |
| ZIP | 46278 |
| Taxonomy | Pharmacy |
| NPI Enumerated | August 8, 2011 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.2M |
| Medicaid | $17.8K |
Provider is effectively Medicare-dominated on scale: lifetime Medicare revenue is reported as $6.2M compared with just $17.8K in Medicaid revenue, indicating Medicare accounts for the overwhelming share of billed dollars for PHARMANEEK INC. The Medicaid footprint is present but minimal relative to Medicare, so analyses of this entity’s financial exposure should focus primarily on Medicare activity.
Medicare revenue is highly concentrated: the precomputed top 3 Medicare codes account for 100.0% of the provider’s Medicare revenue, with K1034 alone reported at $6.3M (99.5% of this provider's total Medicare revenue). This concentration shows that virtually all Medicare dollars flow through a single service line—provision of nonprescription self-administered COVID-19 tests—making that code the primary driver of the provider’s Medicare business.
Business and service-line implication from the Medicare mix: the dominance of K1034 (Provision of covid-19 test, nonprescription self-administered and self-collected use) together with a smaller share from G0108 suggests the entity operates as a pharmacy-centered distributor of test kits and also delivers some individual diabetes self-management training. The code mix indicates a retail pharmacy model augmented by billable patient education services rather than a clinical primary-care practice.
Competitive standing nationally on Medicare K1034 and G0108: K1034 ranks #77 of 30143 providers nationally (100th percentile; extreme outlier), signaling that PHARMANEEK INC is a major national outlier in volume for COVID self-test provision. The Medicare G0108 activity is also an outlier (ranks #8 of 1168, 99th percentile; extreme outlier) but represents a very small portion of Medicare dollars (0.5%), so the firm’s national prominence is overwhelmingly tied to K1034.
Medicaid revenue concentration and service mix: the top 3 Medicaid codes account for 98.2% of the provider’s Medicaid revenue, led by G0108 at $14K (80.5% of Medicaid revenue), A4253 at $2.1K (11.8%), and K1034 at $1K (5.9%). Medicaid billing therefore centers on diabetes education (G0108) and diabetes supplies (A4253), with a smaller role for COVID self-test provisioning under Medicaid.
Competitive standing in-state for Medicaid services: the provider ranks #2 of 19 for G0108 in-state (94th percentile; notably above typical state volume) and #3 of 184 for A4253 (99th percentile; extreme outlier). These ranks indicate PHARMANEEK INC is a prominent Medicaid supplier of diabetes education and glucose test strips within Indiana, even though dollar volumes to Medicaid are modest in absolute terms.
Operational implications and ancillary services: Medicaid claims also show small volumes of DME/inhalation products (J7613, J7620) and remote monitoring setup (99453) but with negligible revenue, reinforcing that the core Medicaid offerings are diabetes-related services and supplies. Taken together across payers, the pattern is consistent with a pharmacy that mixes high-volume product distribution (tests and strips) with reimbursable patient education services.
Tenure and strategic note: the NPI was enumerated on 2011-08-08 (~15 years ago), indicating an established provider presence; the sustained listing combined with the very high K1034 volumes suggests PHARMANEEK INC scaled or shifted operations to capitalize on high-volume COVID test provisioning while maintaining diabetes-related services for Medicaid and Medicare beneficiaries.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 4,660 | $1 | $14K |
| A4253 | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips | 2,050 | $1 | $2.1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,020 | $1 | $1K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 190 | $1 | $190 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 60 | $1 | $120 |
| 99453 | The provider sets up equipment for remote physiologic monitoring and educates the patient on how to use it. | 90 | $0 | $0 |
| A4259 | Lancets, per box of 100 | 150 | $0 | $0 |
| Q0513 | Pharmacy dispensing fee for inhalation drug(s); per 30 days | 660 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Indiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Indiana median
8 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 2 | 20 | 280 | $50 | $58.1K |
| A4259 | Lancets, per box of 100 | 6 | 20 | 60 | $1 | $2.1K |
| A4253 | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips | 3 | 180 | 60 | $10 | $1.4K |
| 99453 | The provider sets up equipment for remote physiologic monitoring and educates the patient on how to use it. | 5 | 10 | 60 | $1 | $450 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 8 | 40 | 50 | $1 | $60 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 7 | 20 | 40 | $1 | $30 |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2 | 40 | 30 | $1 | $20 |
| Q0513 | Pharmacy dispensing fee for inhalation drug(s); per 30 days | 3 | 20 | 80 | $1 | $1 |
Other providers in the same ZIP code as Pharmaneek Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Patients Choice Laboratories Of Indiana, LLC | IN | Clinical Medical Laboratory | $17.3M | $23.4M |
| American Health Network Of Indiana, LLC | IN | Internal Medicine Physician | $0 | $15.3M |
| Kci Usa Inc. | IN | Durable Medical Equipment & Medical Supplies | $0 | $10.1M |
| Landmark Recovery Of Carmel LLC | IN | Substance Abuse Rehabilitation Facility | $0 | $6.4M |
| Aria Diagnostics LLC | IN | Clinical Medical Laboratory | $647.7K | $3.9M |
| Kacy Rogers | IN | Nurse Practitioner | $643.1K | $0 |
| Brian Wiegel | IN | Diagnostic Radiology Physician | $446.5K | $0 |
| Timothy Davis | IN | Diagnostic Radiology Physician | $429.5K | $0 |
| Florentino Ferrer | IN | Physical Therapist | $244.3K | $0 |
| Michael Conley | IN | Diagnostic Radiology Physician | $231.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.